"He cannot get his VA benefits, he is having a difficult time doing that, so we are out here today because he and his wife are both disabled and he needs a back surgery really badly, so we are here ...

From liposuction to full body makeovers, In Touch reveals which 90 Day Fiancé cast members have gotten candid about their plastic surgery procedures over the years. Larissa Dos Santos Lima has ...

Nachrichten»Endospan Announces Positive 30-Day Data from TRIOMPHE FDA Clinical Study of NEXUS Aortic Arch Stent-Graft Push Mitteilungen Business Wire 05.05.2025 14:36 Uhr 170 Leser Artikel ...

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal Dr. Bradley Leshnower, Professor of ...

--Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105 th ...

It was reported during the session that the 30-day results from the TRIOMPHE study are promising for aortic arch treatment in Zone 0 with the NEXUS Aortic Arch Stent-Graft System.

PR Newswire ATLANTA, May 5, 2025 30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ...

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the ...

TEL AVIV, Israel — Endospan today announced the presentation of 30-day results of the statistical Dissection Primary Arm from the TRIOMPHE Investigational Device Exemption (IDE) clinical study ...

By Artivion, Inc. May 5, 2025 May 5, 2025Updated May 5, 2025 (PRNewsfoto/Artivion, Inc.) By Artivion, Inc. 30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major ...

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA, May 5, 2025 /PRNewswire ...